Advertisement

Akari Therapeutics, Plc AKTX

Set alert

Price alert · AKTX

All alert types
8.24 USD +0.24 +3.00%

At close · Oct 30

8.00 -0.24 -2.91%

After hours · Oct 30, 4:00 PM ET

Bid
8.00 × 7
Ask
8.25 × 14
8.07 Day range 8.95
3.06 52-week range 32.80
YTD
-28.72%
1 year
-71.78%
Open
8.50
Prev close
8.00
Mkt cap
18.83M
Vol
45.80K
Avg vol
62.34K
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
8.07
High
8.95
Forward P/E
-0.29
Beta
0.95
Short ratio
1.92
Inst. own
0.51%
Dividend
0.00
Ex-div date
Earnings
May 6, 2024
50-d avg
1.78
200-d avg
2.41
1y target
0.00

5D chart

Chart tools
Interval

Signals (79)
NameTimeAgo
SMA: BearishOct 30, 11:00 AM2 days ago
SMA: BullishOct 30, 10:45 AM2 days ago
SMA: BullishOct 30, 10:30 AM2 days ago
SMA: BullishOct 30, 10:25 AM2 days ago
SMA: BearishOct 30, 10:20 AM2 days ago
SMA: BearishOct 30, 10:15 AM2 days ago
SMA: BullishOct 30, 9:55 AM2 days ago
MACD: Buy SignalOct 30, 9:35 AM2 days ago
SMA: BullishOct 30, 9:30 AM2 days ago
SMA: BearishOct 29, 3:25 PM2 days ago
RSI: OversoldOct 29, 3:25 PM2 days ago
SMA: BullishOct 29, 3:20 PM2 days ago
RSI: OversoldOct 29, 2:10 PM2 days ago
SMA: BearishOct 29, 1:50 PM2 days ago
MACD: Sell SignalOct 29, 1:40 PM2 days ago
MACD: Buy SignalOct 29, 1:20 PM2 days ago
SMA: BullishOct 29, 1:05 PM2 days ago
SMA: BullishOct 29, 1:05 PM2 days ago
SMA: BearishOct 29, 12:45 PM2 days ago
SMA: BearishOct 29, 12:45 PM2 days ago
SMA: BearishOct 29, 12:25 PM2 days ago
MACD: Sell SignalOct 29, 12:25 PM2 days ago
SMA: BullishOct 29, 12:20 PM2 days ago
MACD: Buy SignalOct 29, 12:20 PM2 days ago
MACD: Sell SignalOct 29, 12:15 PM2 days ago
SMA: BearishOct 29, 12:10 PM2 days ago
SMA: BullishOct 29, 11:50 AM3 days ago
SMA: BearishOct 29, 11:40 AM3 days ago
SMA: BullishOct 29, 10:50 AM3 days ago
SMA: BullishOct 29, 10:50 AM3 days ago
MACD: Buy SignalOct 29, 10:50 AM3 days ago
SMA: BearishOct 29, 10:15 AM3 days ago
MACD: Sell SignalOct 29, 10:15 AM3 days ago
MACD: Buy SignalOct 29, 10:05 AM3 days ago
SMA: BearishOct 29, 9:55 AM3 days ago
SMA: BullishOct 29, 9:50 AM3 days ago
SMA: BullishOct 29, 9:50 AM3 days ago
SMA: BearishOct 28, 3:20 PM3 days ago
SMA: BearishOct 28, 3:20 PM3 days ago
MACD: Sell SignalOct 28, 3:20 PM3 days ago
RSI: OversoldOct 28, 3:20 PM3 days ago
MACD: Buy SignalOct 28, 3:05 PM3 days ago
RSI: OverboughtOct 28, 3:05 PM3 days ago
SMA: BearishOct 28, 11:35 AM4 days ago
MACD: Sell SignalOct 28, 11:35 AM4 days ago
MACD: Buy SignalOct 28, 11:25 AM4 days ago
MACD: Sell SignalOct 28, 11:20 AM4 days ago
SMA: BullishOct 28, 9:40 AM4 days ago
SMA: BullishOct 28, 9:40 AM4 days ago
RSI: OverboughtOct 28, 9:40 AM4 days ago
MACD: Buy SignalOct 27, 3:05 PM4 days ago
SMA: BearishOct 27, 2:15 PM4 days ago
SMA: BullishOct 27, 1:55 PM4 days ago
SMA: BearishOct 27, 1:15 PM4 days ago
RSI: OversoldOct 27, 1:15 PM4 days ago
MACD: Sell SignalOct 27, 12:25 PM4 days ago
MACD: Buy SignalOct 27, 11:20 AM5 days ago
RSI: OverboughtOct 27, 11:20 AM5 days ago
SMA: BullishOct 27, 11:10 AM5 days ago
MACD: Sell SignalOct 27, 10:40 AM5 days ago
SMA: BearishOct 27, 10:25 AM5 days ago
RSI: OverboughtOct 27, 9:55 AM5 days ago
SMA: BullishOct 27, 9:40 AM5 days ago
MACD: Buy SignalOct 27, 9:40 AM5 days ago
RSI: OversoldOct 26, 3:45 PM5 days ago
RSI: OversoldOct 26, 2:50 PM5 days ago
RSI: OversoldOct 26, 2:30 PM5 days ago
SMA: BearishOct 26, 2:15 PM5 days ago
MACD: Sell SignalOct 26, 2:00 PM5 days ago
SMA: BullishOct 26, 12:55 PM5 days ago
SMA: BullishOct 26, 12:55 PM5 days ago
MACD: Buy SignalOct 26, 12:55 PM5 days ago
SMA: BearishOct 26, 12:45 PM5 days ago
MACD: Sell SignalOct 26, 12:45 PM5 days ago
MACD: Buy SignalOct 26, 12:35 PM5 days ago
SMA: BearishOct 26, 12:15 PM5 days ago
SMA: BullishOct 26, 12:10 PM5 days ago
SMA: BullishOct 26, 12:10 PM5 days ago
RSI: OverboughtOct 26, 12:10 PM5 days ago

Key statistics

Market cap
25.94M
Enterprise value
35.14B
Trailing P/E
0.00
Forward P/E
-0.29
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-2.58
Beta
0.95
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-7.51M
Total cash
4.18M
Total debt
1.00M
Return on equity
0.00%
Shares outstanding
26.47M
Short % of float
0.23%
50-day average
1.78
200-day average
2.41

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

May 6, 2024

Expected May 6, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
AKTX Revenue — quarterly 0
2022-Q2 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AKTX Net income — quarterly -4.81M
2022-Q2 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AKTX EPS — quarterly 0.00
2022-Q2 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AKTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 6, 2024Dec 1, 20230.00———
Oct 3, 2023Jun 1, 20230.00———
Jul 19, 2023Mar 1, 20230.00———
May 15, 2023Dec 1, 20220.00———
Jan 6, 2023Sep 1, 20220.00———
Sep 27, 2022Jun 1, 20220.00-2.00——

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
akaritx.com

News

Your note

Sign in to keep a note on AKTX — it syncs with the Stock Master app.

Insider holders

AKTX insider holders
InsiderRelationLatest transactionDateShares held
DICICCO WENDY FRANCESChief Financial OfficerStock Award(Grant)Apr 30, 2024158,474,000
PATEL SAMIR RASHMIKANTDirectorStock Award(Grant)Jun 27, 20243,502,890,000
PRUDO-CHLEBOSZ RAYMOND M.D.DirectorStock Award(Grant)Dec 1, 20244,916,600,000

Institution ownership

AKTX institution ownership
Holder% heldSharesValueReported
Omnia Family Wealth, LLC0.33%87,62885.88KSep 29, 2024
Citadel Advisors Llc0.13%33,26032.59KSep 29, 2024
Cerity Partners LLC0.09%23,64323.17KSep 29, 2024
Renaissance Technologies, LLC0.07%18,06917.71KSep 29, 2024
Cresset Asset Management, LLC0.07%18,40818.04KSep 29, 2024
Cornerstone Planning Group LLC 0.00%54Sep 29, 2024

Fund ownership

AKTX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.01%1,5121.48KOct 30, 2024
Advertisement